The FDA is increasing its scrutiny of foreign drug manufacturing facilities, which produce a large portion of the medicines and drug ingredients used in the U.S. This renewed focus comes after inspections were disrupted during the pandemic and amid growing concerns about quality control and supply chain vulnerabilities. The article discusses the challenges the FDA faces in overseeing a vast global network of manufacturers. It also covers the potential risks to the U.S. drug supply from quality issues at these overseas plants.
